Testing TEV-56286 for Multiple System Atrophy
Part of Brain & nervous system clinical trials.
This trial tests a new drug called TEV-56286 for people with Multiple System Atrophy (MSA), a rare brain disorder. It aims to see if the drug can help control symptoms and slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with possible or probable Multiple System Atrophy (MSA) by a doctor using standard criteria.
- You are in stable health, both physically and mentally, as confirmed by your medical history and exams.
- Women who can get pregnant must have a negative pregnancy test and use highly effective birth control during the study.
- Men who are fertile and their partners must use highly effective birth control together.
- You cannot have two or more relatives with MSA, or have a history of alcohol or drug abuse in the past year.
- You cannot be pregnant, breastfeeding, or have used any other experimental drug in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug TEV-56286 continues to work for multiple system atrophy (a rare brain disorder). It is for people who already completed a previous study of the same drug.
This early-phase trial tests a new drug called ALT001 for people with multiple system atrophy (MSA). It aims to see if the drug is safe and may help slow the disease.
This study tests a new antibody drug that targets a protein linked to multiple system atrophy (MSA). It aims to see if the drug is safe and may slow the disease, for people recently diagnosed.
This Phase 1 study checks how safe a drug called ION464 is, how the body handles it, and how much of the drug reaches the bloodstream in adults with multiple system atrophy (MSA). It may help researchers find a dosing approach for future treatments for MSA.
This trial tests whether a medication called butylphthalide can help slow or improve symptoms of multiple system atrophy (MSA), a rare neurological condition that affects movement, balance, and automatic body functions. The study will measure how well the drug works and how safe it is for patients.
This trial tests a nasal spray called Foralumab for people with multiple system atrophy (MSA). The goal is to see if the spray can help reduce symptoms or slow the disease. It is for people who are otherwise healthy enough to safely participate.
Hear when a new Multiple System Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.